Press Releases Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-12 EDT			5-day change	1st Jan Change
76.59 ^EUR	+0.38%		-1.74%	-7.41%

06-13	Sanofi - Shareholder/Analyst Call
06-12	FDA approves expanded use of Sanofi's type 1 diabetes drug	RE

Press Releases

06-12	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	GL
06-10	Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy	GL
06-08	Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector	GL
06-04	Sanofi federates the healthcare ecosystem to accelerate the diagnosis of rare diseases in France, Biogen joins accelRare	AQ
06-04	Sanofi launches 2026 global employee stock purchase plan	GL
06-02	UPC Turns Three: Statistics, Milestones, And Trends	AQ
05-29	Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease	AQ
05-28	Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease	GL
05-18	ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD	GL
04-29	Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi	GL
04-27	Sanofi's Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses	AQ
04-24	Sanofi successfully prices 2.3 billion of bond issue	GL
04-24	Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses	GL
04-23	Phase 3 EMN24 IsKia Study: Quadruplet Isa-KRd Regimen Significantly Improves MRD Negativity in Newly Diagnosed Multiple Myeloma \| DelveInsight's Perspective on Treatment Paradigm Shift	AQ
04-23	Q1 2026: double-digit sales and business EPS growth	GL
04-22	Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria	GL
04-22	Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children	GL
04-22	Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US	GL
04-18	ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study	GL
04-13	Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	GL
04-08	Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents	GL
04-07	Sanofi : lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP	PU
04-07	Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP	GL
04-01	Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease	AQ
03-31	Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease	GL